Antibody Targeting Kit Receptor D4 Domain for Inactive State Locking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective methods to characterize and target specific regions of receptor tyrosine kinases like Kit and PDGFR for therapeutic intervention, particularly in inhibiting their activity to prevent diseases such as cancer.
Innovation Solution
Development of antibodies or antigen binding portions that bind to specific epitopes on the ectodomain of receptor tyrosine kinases, locking them in an inactive state by preventing dimerization or altering the positioning of Ig-like domains, thereby inhibiting tyrosine autophosphorylation and downstream signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to target receptor tyrosine kinases, then general inhibition may be achieved, but specific regional targeting and precise mechanistic understanding are lacking
Solution Approach 1:
The invention divides the receptor tyrosine kinase into functional segments (ectodomain, transmembrane domain, cytoplasmic domain) and targets specific epitopes within these segments. The antibody is designed to bind to particular Ig-like domains (D1-D5) of the ectodomain, allowing precise regional targeting rather than general receptor inhibition. This segmentation enables the antibody to interfere with specific functional regions while leaving other parts of the receptor intact.
Solution Approach 2:
The invention applies local quality by creating an antibody with specific affinity for particular epitopes on the Kit receptor ectodomain. The antibody's binding properties are optimized for specific regions (such as the D4 domain involved in dimerization or D5 domain involved in ligand binding), allowing different local effects on receptor function. This enables precise control over which aspects of receptor activity are inhibited.
2Reliability
If the antibody binds to the ectodomain to lock it in an inactive state, then receptor activity is inhibited, but the mechanism of preventing dimerization and autophosphorylation must be precisely characterized
Solution Approach 1:
The antibody is designed to bind to the ectodomain in advance, preventing the conformational changes and interactions that would lead to activation. By binding to specific epitopes on the inactive conformation, the antibody locks the receptor in an inactive state before activation can occur, preventing dimerization and subsequent autophosphorylation events.
Solution Approach 2:
The antibody acts as an intermediary molecule that binds between the ligand and the receptor's active site. By occupying specific epitopes on the ectodomain, the antibody prevents ligand binding or receptor dimerization without directly interfering with the catalytic activity of the kinase domain. This intermediary approach allows precise control over activation while maintaining the integrity of the receptor structure.
3Object-affected harmful factors
If gain-of-function mutations in the D5 domain are targeted, then cancer-related Kit activity can be inhibited, but the molecular mechanism underlying these mutations is not fully understood
Solution Approach 1:
The invention addresses gain-of-function mutations by designing antibodies that bind to the D5 domain with high specificity. These mutations alter parameters such as ligand binding affinity and receptor dimerization propensity. The antibody counteracts these parameter changes by binding to epitopes that stabilize the inactive conformation or block the mutated regions, thereby restoring normal regulatory control over Kit activity.
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
The present invention provides moieties that bind to an Ig-like domain, e.g., D4 or D5, of a human receptor tyrosine kinase, e.g., the human Kit RTK or the PDGFR RTK, or the D7 domain of a type V receptor tyrosine kinase wherein the moieties lock the ectodomain of the receptor tyrosine kinase in an inactive state thereby antagonizing the activity of the receptor tyrosine kinase.